Stryker (SYK) Competitors

Stryker has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Boston Scientific has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Stryker has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

In the previous week, Boston Scientific had 12 more articles in the media than Stryker. MarketBeat recorded 47 mentions for Boston Scientific and 35 mentions for Stryker. Boston Scientific's average media sentiment score of 1.51 beat Stryker's score of 1.50 indicating that Boston Scientific is being referred to more favorably in the media.

Boston Scientific has a net margin of 17.29% compared to Stryker's net margin of 13.20%. Stryker's return on equity of 23.42% beat Boston Scientific's return on equity.

Boston Scientific presently has a consensus target price of $85.08, indicating a potential upside of 87.81%. Stryker has a consensus target price of $395.33, indicating a potential upside of 28.10%. Given Boston Scientific's stronger consensus rating and higher possible upside, research analysts clearly believe Boston Scientific is more favorable than Stryker.

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.3% of Boston Scientific shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Cardinal Health pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. Stryker pays out 40.7% of its earnings in the form of a dividend. Cardinal Health pays out 31.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 32 consecutive years and Cardinal Health has raised its dividend for 29 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Cardinal Health has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Stryker has higher earnings, but lower revenue than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker presently has a consensus target price of $395.33, indicating a potential upside of 28.10%. Cardinal Health has a consensus target price of $246.93, indicating a potential upside of 11.19%. Given Stryker's higher possible upside, equities research analysts clearly believe Stryker is more favorable than Cardinal Health.

In the previous week, Stryker had 27 more articles in the media than Cardinal Health. MarketBeat recorded 35 mentions for Stryker and 8 mentions for Cardinal Health. Stryker's average media sentiment score of 1.50 beat Cardinal Health's score of 0.93 indicating that Stryker is being referred to more favorably in the media.

Stryker has a net margin of 13.20% compared to Cardinal Health's net margin of 0.62%. Stryker's return on equity of 23.42% beat Cardinal Health's return on equity.

77.1% of Stryker shares are held by institutional investors. Comparatively, 87.2% of Cardinal Health shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Comparatively, 0.1% of Cardinal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Cencora has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Stryker presently has a consensus price target of $395.33, suggesting a potential upside of 28.10%. Cencora has a consensus price target of $374.00, suggesting a potential upside of 37.51%. Given Cencora's stronger consensus rating and higher probable upside, analysts clearly believe Cencora is more favorable than Stryker.

In the previous week, Stryker had 30 more articles in the media than Cencora. MarketBeat recorded 35 mentions for Stryker and 5 mentions for Cencora. Stryker's average media sentiment score of 1.50 beat Cencora's score of 0.75 indicating that Stryker is being referred to more favorably in the media.

Stryker has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 97.5% of Cencora shares are owned by institutional investors. 4.6% of Stryker shares are owned by insiders. Comparatively, 0.4% of Cencora shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Stryker has a net margin of 13.20% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Stryker's return on equity.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.9%. Stryker pays out 40.7% of its earnings in the form of a dividend. Cencora pays out 18.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 32 consecutive years and Cencora has increased its dividend for 15 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Stryker had 24 more articles in the media than DaVita. MarketBeat recorded 35 mentions for Stryker and 11 mentions for DaVita. Stryker's average media sentiment score of 1.50 beat DaVita's score of 0.73 indicating that Stryker is being referred to more favorably in the media.

Stryker has a net margin of 13.20% compared to DaVita's net margin of 5.65%. Stryker's return on equity of 23.42% beat DaVita's return on equity.

Stryker presently has a consensus target price of $395.33, suggesting a potential upside of 28.10%. DaVita has a consensus target price of $199.17, suggesting a potential downside of 4.08%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than DaVita.

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, DaVita has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

77.1% of Stryker shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Comparatively, 1.5% of DaVita shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.